Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed primary supratentorial glioma
• * Multifocal disease allowed
• Recurrent disease after prior surgery and/or radiotherapy
• Radiological evidence of increased and/or enhanced target lesion
• Amenable to temozolomide therapy
• PATIENT CHARACTERISTICS:
• Age
• Over 18
• Performance status
• ECOG 0-2 OR
• WHO 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 10.0 g/dL
• Hepatic
• Alkaline phosphatase \< 2.5 times upper limit of normal (ULN)
• Transaminases \< 2.5 times ULN
• Bilirubin \< 1.5 times ULN
• Renal
• Creatinine \< 1.7 mg/dL
• Cardiovascular
• Cardiac function clinically normal
• Normal 12-lead ECG
• QTc ≤ 440 msec on ECG
• No ischemic heart disease within the past 6 months
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after study participation
• No unstable systemic disease
• No active uncontrolled infection
• No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up
• No other active or recurrent malignancy within the past 5 years except cone biopsied carcinoma of the cervix or adequately treated basal cell or squamous cell skin cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent anticancer biologic agents
• Chemotherapy
• At least 4 weeks since prior chemotherapy (6 weeks for temozolomide)
• Prior adjuvant chemotherapy allowed
• No more than 1 prior chemotherapy regimen for recurrent disease
• No other concurrent chemotherapy
• Endocrine therapy
• Concurrent corticosteroids allowed provided treatment remains at a stable or decreasing dose for at least 2 weeks
• Radiotherapy
• See Disease Characteristics
• No concurrent radiotherapy
• Surgery
• See Disease Characteristics
• At least 3 months since prior surgery for primary brain tumor
• Other
• Concurrent anticonvulsants allowed
• No other concurrent anticancer agents
• No other concurrent investigational therapy